Stock listing

NASDAQ:AURA Aura Biosciences, Inc. Stock

Home listing (NASDAQ) of Aura Biosciences, Inc.

Follow Aura Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:AURA

$6.87 USD -0.27 (-3.8%)

Close on Nov 20, 2026

Past year +28.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.51 – $6.98 USDNov 20, 2026
Volume
791,133 sharesNov 20, 2026
Market cap
$715.0M USDAt the close on Nov 20, 2026 · price × 104.1M shares outstanding
52-week range
$4.73 – $9.54 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$5.64M USDMedian day 762,494 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Aura Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AURA · Home$6.87 USD-0.27 (-3.8%)791,133$6.505$6.975$6.505$7.14Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AURA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$6.87-0.27-3.8%$6.505$6.975$6.505791,133
$7.14-0.01-0.1%$7.17$7.24$7.00687,840
$7.15-0.07-1.0%$7.20$7.305$7.00627,640
$7.22+0.11+1.5%$7.05$7.29$6.95779,116
$7.110.000.0%$7.24$7.24$6.865610,303
$7.11-0.50-6.6%$7.53$7.53$7.061,006,708
$7.61-0.04-0.5%$7.71$7.715$7.31648,547
$7.65-0.01-0.1%$7.65$7.945$7.42875,183
$7.66+1.10+16.8%$6.67$7.70$6.621,128,663
$6.56+0.22+3.5%$6.35$6.66$6.17859,019
$6.34-0.31-4.7%$6.55$6.63$6.27790,866
$6.65+0.41+6.6%$6.42$6.66$6.2551,001,928
$6.24+0.21+3.5%$6.07$6.325$6.045643,057
$6.03-0.11-1.8%$6.13$6.16$5.88746,584
$6.14-0.155-2.5%$6.30$6.43$6.03533,013
$6.295-0.105-1.6%$6.46$6.51$6.26769,975
$6.40+0.10+1.6%$6.27$6.41$6.21541,882
$6.30+0.12+1.9%$6.20$6.31$6.095680,261
$6.18-0.12-1.9%$6.31$6.42$6.145907,585
$6.30-0.16-2.5%$6.33$6.40$6.16722,144
$6.460.000.0%$6.46$6.59$6.35955,317
$6.46-0.10-1.5%$6.46$6.61$6.385933,595
$6.56+0.27+4.3%$6.32$6.77$6.181,164,028
$6.29+0.19+3.1%$6.13$6.37$6.12556,794
$6.10-0.24-3.8%$6.31$6.355$6.095762,494
$6.34+0.17+2.8%$6.23$6.415$6.17604,522
$6.17-0.10-1.6%$6.21$6.28$6.0851,009,778
$6.27-0.27-4.1%$6.53$6.56$6.181,663,238
$6.540.000.0%$6.55$6.70$6.50613,137
$6.54+0.035+0.5%$6.48$6.70$6.46962,557
$6.505+0.045+0.7%$6.41$6.61$6.361,692,188
$6.46+0.29+4.7%$6.10$6.563$6.10723,720
$6.17-0.05-0.8%$6.26$6.27$6.10607,526
$6.22+0.13+2.1%$6.09$6.42$6.05589,813
$6.09+0.05+0.8%$6.11$6.15$5.972,099,065
$6.04-0.24-3.8%$6.36$6.36$6.00807,346
$6.28+0.13+2.1%$6.21$6.36$6.12677,458
$6.150.000.0%$6.13$6.175$6.04795,446
$6.15+0.15+2.5%$6.03$6.17$6.00483,657
$6.00-0.15-2.4%$6.18$6.18$5.9851,116,505
$6.15+0.13+2.2%$6.01$6.25$5.95963,075
$6.02-0.43-6.7%$6.42$6.47$5.981,037,128
$6.45+0.09+1.4%$6.32$6.46$6.27601,580
$6.36-0.08-1.2%$6.52$6.54$6.25819,096
$6.44-0.15-2.3%$6.73$6.73$6.433,776,734
$6.59-0.14-2.1%$6.84$6.88$6.46916,382
$6.73-0.19-2.7%$6.92$7.01$6.591,294,176
$6.92-0.09-1.3%$7.11$7.11$6.605712,285
$7.01+0.015+0.2%$7.14$7.16$6.94467,415
$6.995+0.005+0.1%$7.08$7.08$6.91830,854
$6.99-0.21-2.9%$7.14$7.195$6.93785,541
$7.20-0.16-2.2%$7.34$7.39$7.16465,897
$7.36-0.20-2.6%$7.48$7.56$7.28507,752
$7.56+0.19+2.6%$7.30$7.57$7.30456,395
$7.37-0.13-1.7%$7.58$7.635$7.26875,874
$7.50+0.07+0.9%$7.46$7.67$7.00495,494
$7.43+0.25+3.5%$7.11$7.515$7.11534,540
$7.18-0.22-3.0%$7.39$7.40$7.06602,504
$7.40-0.30-3.9%$7.66$7.79$7.36441,402
$7.70-0.03-0.4%$7.70$7.81$7.64440,769
$7.73-0.09-1.2%$7.76$7.78$7.60557,598
$7.82-0.08-1.0%$7.95$8.105$7.761,131,945
$7.90+0.10+1.3%$7.80$8.00$7.60843,826
$7.80+0.03+0.4%$7.77$8.085$7.65500,883
$7.77-0.02-0.3%$7.70$7.78$7.415643,062
Ticker
NASDAQ:AURA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Aura Biosciences, Inc. news

Aura Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 76 in all · newest Nov 9, 2026 · oldest 2021
Decks
31 decks · latest Nov 9, 2026

Where Aura Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AURA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:AURABOATSUnited StatesUSD

Valuation

Price/book 2.5× against a median of 2.2×: 7th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$433.9M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.07

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Aura Biosciences, Inc. · NASDAQ:AURAUS$715.0MUS$433.9Mn/an/an/a2.5×n/a0.1×1.07
Inventiva SA · EURONEXT:IVAUS$760.9MUS$577.3Mn/a117×n/a11.8×n/a1.1×n/a
Rigel Pharmaceuticals, Inc. · NASDAQ:RIGLUS$754.9MUS$663.4M2.5×2.3×8.3×1.7×106.6%0.0×1.02
Obsidian Therapeutics, Inc. · NASDAQ:OBXUS$741.3MUS$530.4M13.0×n/an/a2.3×n/a0.0×n/a
Monte Rosa Therapeutics, Inc. · NASDAQ:GLUEUS$738.3MUS$196.8Mn/a2.8×n/a1.5×−186.2%0.1×0.92
Aimed Bio Inc. · KRX:0009K0US$726.5MUS$657.3M25.2×13.2×34.0×4.8×57.8%0.0×n/a
Solid Biosciences Inc. · NASDAQ:SLDBUS$697.6MUS$368.3Mn/an/an/a2.0×n/a0.1×1.85
Attovia Therapeutics, Inc. · NASDAQ:ATTOUS$689.3MUS$297.2Mn/a220×n/a1.7×n/a0.0×n/a
Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRXUS$681.2MUS$549.9Mn/a14.3×n/a4.2×−161.8%0.3×1.15
CARsgen Therapeutics Holdings Ltd. · HKEX:2171US$676.0MUS$477.2Mn/a25.4×n/a4.1×−77.9%0.1×n/a
Philogen SpA · MIL:PHILUS$672.3MUS$532.7M2.7×1.5×n/a1.6×71.8%0.0×n/a
Median of the othersUS$712.1MUS$531.6M7.8×13.7×21.2×2.2×−10.1%0.0×1.09

Forecasts

5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
16.60 USD · Analysts' mean
EPS, year to Dec 2026
-1.50 · 4 analysts

Team and board

Officers

OfficerRole
Natalie HollesChief Executive Officer and President and member of the Board
Jill HopkinsChief Medical Officer, President of Research & Development
Susan Abu-AbsiChief Operating Officer
Amy ElazzouziPrincipal Accounting Officer, Senior Vice President of Finance and Treasurer
Anthony DanielsVice President, Therapeutic Area Head Ocular Oncology
Patrick NealonSenior Vice President, Clinical Development Operations
Erica KratzChief Regulatory and Quality Officer
Julie PersonChief People Officer

Board

DirectorRole
David JohnsonChairman
Antony MattessichDirector
Giovanni MariggiDirector
Jeremy BenderDirector
Natalie HollesChief Executive Officer and President and member of the Board
Sapna SrivastavaDirector
Teresa BitettiDirector

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open+16.8%
Q2 2026Aug 11, 2026 · Before open+4.4%
Q1 2026May 7, 2026+1.3%
Q4 2025Mar 30, 2026 · Before open−1.1%
Q3 2025Nov 13, 2025 · Before open−0.7%
Q2 2025Aug 13, 2025 · Before open+4.2%
Q1 2025May 15, 2025+21.4%
Q4 2024Mar 24, 2025 · After close+1.1%
Q3 2024Nov 12, 2024 · After close−3.0%
Q2 2024Aug 8, 2024 · Before open+3.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open+2.0%
Q4 2023Mar 12, 2024 · After close−0.8%
Q3 2023Nov 9, 2023 · After close+9.5%
Q2 2023Aug 9, 2023 · Before open−6.6%
Q1 2023May 11, 2023 · After close+0.4%
Q4 2022Mar 15, 2023 · After close+0.3%
Q3 2022Nov 10, 2022 · Before open+1.9%
Q2 2022Aug 11, 2022 · After close+8.9%
Q1 2022May 12, 2022 · After close+5.8%
Q4 2021Mar 23, 2022 · After close+3.2%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (November 2026)Corporate update21 slidesNov 9, 2026
Corporate Update (August 2026)Corporate update21 slidesAug 11, 2026
Investor Presentation (May 2026)Investor deck50 slidesMay 11, 2026
Corporate Update (November 2025)Corporate update45 slidesNov 13, 2025
Investor Presentation (August 2025)Investor deck54 slidesAug 13, 2025
Investor Presentation (May 2025)Investor deck51 slidesMay 16, 2025
Investor Presentation (March 2025)Investor deck59 slidesMar 24, 2025
EAU 2025 Research ForumConference12 slidesMarch 2025
EAU 2025Conference10 slidesMarch 2025
Corporate Update (November 2024)Corporate update43 slidesNov 12, 2024
All 31 decks
DeckKindSlidesDate
Corporate Update (October 2024)Corporate update41 slidesOct 17, 2024
Investor Presentation (September 2024)Investor deck33 slidesSep 12, 2024
Investor Presentation (August 2024)Investor deck35 slidesAug 8, 2024
Investor Presentation (June 2024)Investor deck33 slidesJun 4, 2024
Technical Presentation (May 2024)Technical20 slidesMay 24, 2024
Investor Presentation (January 2024)Investor deck41 slidesJan 8, 2024
Investor Presentation (November 2023)Investor deck42 slidesNov 6, 2023
AAO 2023Conference19 slidesNov 1, 2023
Investor Presentation (August 2023)Investor deck34 slidesAug 9, 2023
Investor Presentation (May 2023)Investor deck41 slidesMay 11, 2023
Investor Presentation (February 2023)Investor deck41 slidesFeb 16, 2023
Investor Presentation (January 2023)Investor deck37 slidesJan 6, 2023
Investor Presentation (November 2022)Investor deck41 slidesNov 30, 2022
Investor Presentation (October 2022)Investor deck46 slidesOct 3, 2022
AAO 2022Conference13 slidesOct 3, 2022
EURETINA 2022Conference12 slidesSeptember 2022
Technical Presentation (September 2022)Technical20 slidesSeptember 2022
ISOO 2022Conference38 slidesJun 22, 2022
ISOO 2022Conference11 slidesJune 2022
Technical Presentation (May 2022)Technical12 slidesMay 2022
ASRS 2021Conference12 slidesOctober 2021

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: US$260.3M · US$6 a share · Leerink Partners +4
Dealers: Leerink Partners (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), LifeSci Capital, Citizens Capital Markets
Use of proceeds: $205.1 million to advance clinical programs incl. early choroidal melanoma, bel-sar registration-enabling activities and general corporate purposes
May 4, 2026
Public offering of equity
Closed: US$75M raised · US$4.9 a share · Warrants at US$4.9 for 60 months · Leerink Partners +4
Dealers: Leerink Partners (co-lead), Evercore ISI (co-lead), LifeSci Capital, Citizens Capital Markets, Scotiabank
Use of proceeds: Advance clinical programs in choroidal melanoma, choroid metastases, ocular surface cancers and bladder cancer, and general corporate purposes
Aug 13, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$14.00 a share on Oct 28, 2021.

Price
US$14.00 a share
Shares offered
5,400,000 shares of common stock
Offering size
US$75.6 million
Underwriters' option
Up to 810,000 more shares
Underwriters
Cowen, SVB Leerink, Evercore ISI, BTIG · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 10, 2021
Filed publiclyOct 8, 2021
Amended onceOct 25, 2021
Shares registered with an exchangeOct 26, 2021
Declared effective by the SECOct 28, 2021
Final prospectus, with the priceNov 1, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Nov 1, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue0000000
Cost of revenue1.22M1.29M1.18M835.0K831.0K509.0K
Gross profit-1.22M-1.29M-1.18M-835.0K-831.0K-509.0K
Research and development90.3M73.3M65.2M42.2M25.2M18.0M19.1M
Selling, general and administrative22.5M22.8M19.8M18.1M10.1M4.16M4.52M
Operating income-112.8M-96.1M-85.0M-60.3M-35.3M-22.2M-24.1M
Depreciation and amortization1.13M1.22M1.29M1.18M831.0K831.0K509.0K
EBITDA-111.7M-94.9M-83.7M-59.1M-34.4M-21.4M-23.6M
Interest expense850.0K13.0K3.00K5.00K
Income before tax-106.1M-86.8M-76.3M-58.8M-35.3M-22.2M-24.2M
Income tax108.0K112.0K137.0K0005.00K
Net income-106.2M-86.9M-76.4M-58.8M-35.3M-22.2M-24.2M
Earnings per share, basic-1.76-1.75-1.93-1.96-8.95-82.06-0.01
Earnings per share, diluted-1.76-1.75-1.93-1.96-8.95-82.06

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents59.5M31.7M41.1M121.6M149.1M17.4M32.5M
Short-term investments84.7M119.4M185.1M67.2M0
Current assets149.7M160.6M231.8M196.7M153.7M18.5M33.3M
Property, plant and equipment2.62M3.21M3.15M5.37M5.25M3.57M3.63M
Total assets169.4M182.5M255.1M223.9M160.0M22.1M37.1M
Accounts payable1.55M2.30M1.79M2.92M2.40M611.0K2.33M
Current liabilities18.4M14.9M12.4M10.5M7.36M2.66M6.15M
Long-term debt49.0K
Total debt17.4M18.8M19.6M20.9M975.0K15.0K49.0K
Total liabilities32.5M30.5M29.2M28.4M7.71M2.74M6.29M
Shareholders' equity136.9M152.0M225.8M195.6M152.3M-108.7M30.8M
Shares outstanding63.6M50.0M49.4M37.8M29.2M381.1K2.92B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-84.7M-79.8M-63.8M-54.6M-32.4M-24.3M-20.7M
Capital spending-447.0K-1.25M-709.0K-1.09M-2.13M-771.0K-2.22M
Free cash flow-85.2M-81.1M-64.6M-55.7M-34.5M-25.1M-22.9M
Cash from investing35.6M68.8M-114.0M-67.9M-2.13M-771.0K-2.22M
Cash from financing77.2M1.59M97.3M95.6M166.3M10.0M39.7M
Dividends paid-39.8M
Share buybacks87.1M166.3M0-13.0K
Change in cash28.0M-9.39M-80.5M-26.8M131.7M-15.1M16.8M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 1, 2026Big-stake noticeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
S-8 · Registration statement for employee plansSep 1, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 21, 2026Other filingsSEC
CORRESP · Letter to the SECAug 18, 2026Other filingsSEC
UPLOAD · Letter from the SECAug 17, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
3 · Initial statement of ownershipAug 12, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
S-3 · Registration statementAug 11, 2026Offer documentSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
8-K · Current reportAug 5, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2026Insider tradeSEC
8-K · Current reportJul 8, 2026Management or board changeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
DEF 14A · Proxy statementJun 29, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementJun 17, 2026Meeting noticeSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMay 19, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 11, 2026Big-stake noticeSEC
8-K · Current reportMay 11, 2026ResultsSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
8-K · Current reportMay 5, 2026Material contractSEC
424B5 · ProspectusMay 4, 2026Offer documentSEC
8-K · Current reportMay 4, 2026ResultsSEC
DEFA14A · Additional proxy materialMay 4, 2026Meeting noticeSEC
S-3MEFMay 4, 2026Other filingsSEC
424B5 · ProspectusMay 4, 2026Offer documentSEC
8-K · Current reportMay 4, 2026Management or board changeSEC
ARS · Annual report to shareholdersApr 20, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 20, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 20, 2026Meeting noticeSEC
144 · Notice of proposed saleApr 16, 2026Other filingsSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 30, 2026Offer documentSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 30, 2026ResultsSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
144 · Notice of proposed saleOct 29, 2025Other filingsSEC
144 · Notice of proposed saleOct 29, 2025Other filingsSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 17, 2025Big-stake noticeSEC
144 · Notice of proposed saleOct 16, 2025Other filingsSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
8-K · Current reportJun 18, 2025Meeting outcomeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 23, 2025Big-stake noticeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 19, 2025Big-stake noticeSEC
144 · Notice of proposed saleMay 16, 2025Other filingsSEC
3 · Initial statement of ownershipMay 16, 2025Insider tradeSEC
8-K · Current reportMay 16, 2025Material contractSEC
424B5 · ProspectusMay 16, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
424B5 · ProspectusMay 15, 2025Offer documentSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 24, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2025Meeting noticeSEC
144 · Notice of proposed saleApr 16, 2025Other filingsSEC
144 · Notice of proposed saleApr 16, 2025Other filingsSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 11, 2025Big-stake noticeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 2, 2025Insider tradeSEC
8-K · Current reportApr 2, 2025Management or board changeSEC
S-8 · Registration statement for employee plansMar 24, 2025Offer documentSEC
10-K · Annual reportMar 24, 2025Annual reportSEC
8-K · Current reportMar 24, 2025ResultsSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
144 · Notice of proposed saleJan 21, 2025Other filingsSEC
144 · Notice of proposed saleJan 21, 2025Other filingsSEC
4 · Change in ownershipJan 21, 2025Insider tradeSEC
4 · Change in ownershipJan 21, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 3, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 3, 2025Big-stake noticeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
144 · Notice of proposed saleNov 18, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
144 · Notice of proposed saleOct 29, 2024Other filingsSEC
144 · Notice of proposed saleOct 29, 2024Other filingsSEC
144 · Notice of proposed saleOct 29, 2024Other filingsSEC
4 · Change in ownershipOct 29, 2024Insider tradeSEC
4 · Change in ownershipOct 29, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2024Insider tradeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
4 · Change in ownershipOct 21, 2024Insider tradeSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
144 · Notice of proposed saleOct 18, 2024Other filingsSEC
144 · Notice of proposed saleOct 18, 2024Other filingsSEC
8-K · Current reportOct 17, 2024Current reportSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
8-K · Current reportSep 27, 2024Management or board changeSEC
8-K · Current reportSep 12, 2024Current reportSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
8-K · Current reportJun 21, 2024Meeting outcomeSEC
DEFA14A · Additional proxy materialJun 14, 2024Meeting noticeSEC
10-K/A · Annual report, amendedJun 14, 2024Annual reportSEC
8-K · Current reportJun 4, 2024Current reportSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
ARS · Annual report to shareholdersApr 25, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2024Meeting noticeSEC
8-K · Current reportApr 15, 2024Management or board changeSEC
PRE 14A · Preliminary proxy statementApr 15, 2024Meeting noticeSEC

This page holds 200 of 388 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Aura Biosciences, Inc.’s releases · as of Nov 4, 2026

Common shares
104,074,302
Fully diluted
104,074,302

Fully diluted

LineSharesAs of
Common shares104,074,302Nov 4, 2026

Warrants and options

Lot
Warrants · US$4.90 · expire about May 2030

Share count over time

CountShares
Nov 4, 2026104,074,302
Sep 30, 2026103,950,771

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
TCG Crossover Management, LLC10.2M9.8%US$63.8MSep 30, 2026
Frazier Life Sciences Management, L.P.7.1M6.8%US$44.6MSep 30, 2026
Vanguard5.57M5.3%US$35MSep 30, 2026
BlackRock5.42M5.2%US$34.1MSep 30, 2026
ADAR1 Capital Management, LLC5.39M5.2%US$33.8MSep 30, 2026
Fcpm III Services B.V.5.25M5.0%US$33MSep 30, 2026
Long Focus Capital Management, LLC5.12M4.9%US$32.2MSep 30, 2026
Adage Capital Partners Gp, L.L.C.4.64M4.5%US$29.1MSep 30, 2026
Caligan Partners LP4.59M4.4%US$28.8MSep 30, 2026
Nantahala Capital Management, LLC3.81M3.7%US$23.9MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Orbimed Advisors LLC3.33M3.2%US$20.9MSep 30, 2026
Medicxi Ventures Management (Jersey) Ltd3.04M2.9%US$19.1MSep 30, 2026
Janus Henderson2.73M2.6%US$17.1MSep 30, 2026
Montanova Capital, LLC2.65M2.5%US$16.6MSep 30, 2026
Ra Capital Management, L.P.2.5M2.4%US$15.7MSep 30, 2026
State Street2.3M2.2%US$14.5MSep 30, 2026
Franklin Templeton2.08M2.0%US$13.8MSep 30, 2026
Geode Capital1.94M1.9%US$12.2MSep 30, 2026
EcoR1 Capital, LLC1.67M1.6%US$10.5MSep 30, 2026
Redmile Group, LLC1.55M1.5%US$9.75MSep 30, 2026
Trails Edge Capital Partners, LP1.44M1.4%US$9.06MSep 30, 2026
Bellevue Group AG1.42M1.4%US$8.91MSep 30, 2026
Foresite Capital Management VI LLC1.33M1.3%US$8.37MSep 30, 2026
Woodline Partners LP1.21M1.2%US$7.6MSep 30, 2026
Balyasny Asset Management L.P.1.19M1.1%US$7.46MSep 30, 2026
Vivo Capital, LLC1.17M1.1%US$7.33MSep 30, 2026
Acorn Capital Advisors, LLC1.03M0.99%US$6.44MSep 30, 2026
Boothbay Fund Management, LLC946K0.91%US$5.94MSep 30, 2026
Goldman Sachs945K0.91%US$5.93MSep 30, 2026
Levin Capital Strategies, L.P.827K0.79%US$5.19MSep 30, 2026
B Group, Inc.764K0.73%US$4.8MSep 30, 2026
Dimensional709K0.68%US$4.45MSep 30, 2026
Stempoint Capital LP647K0.62%US$4.07MSep 30, 2026
Northern Trust607K0.58%US$3.81MSep 30, 2026
Regency Capital Management Inc.\DE533K0.51%US$3.35MSep 30, 2026
Fidelity384K0.37%US$2.41MSep 30, 2026
D. E. Shaw & Co., Inc.329K0.32%US$2.07MSep 30, 2026
Citadel305K0.29%US$1.91MSep 30, 2026
Qube Research & Technologies Ltd272K0.26%US$1.71MSep 30, 2026
XTX Topco Ltd267K0.26%US$1.68MSep 30, 2026
Hrt Financial LP267K0.26%US$1.68MSep 30, 2026
Jump Financial, LLC219K0.21%US$1.37MSep 30, 2026
Quantinno Capital Management LP217K0.21%US$1.36MSep 30, 2026
Trexquant Investment LP213K0.20%US$1.34MSep 30, 2026
Schwab200K0.19%US$1.25MSep 30, 2026
Morgan Stanley197K0.19%US$1.24MSep 30, 2026
Bank of America178K0.17%US$1.12MSep 30, 2026
Y-Intercept (Hong Kong) Ltd174K0.17%US$1.09MSep 30, 2026
Point72 Asset Management, L.P.165K0.16%US$1.03MSep 30, 2026
Wellington159K0.15%US$998KSep 30, 2026

This page holds 50 of 150 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund2.9M2.8%US$20.6MJun 30, 2026
iShares Russell 2000 ETF1.17M1.1%US$8.32MJun 30, 2026
Vanguard Extended Market Index Fund1.11M1.1%US$7.87MJun 30, 2026
Franklin Biotechnology Discovery Fund766K0.74%US$5.37MJul 31, 2026
Fidelity Extended Market Index Fund502K0.48%US$3.75MMay 31, 2026
Fidelity Small Cap Index Fund489K0.47%US$3.43MJul 31, 2026
iShares Biotechnology ETF456K0.44%US$3.24MJun 30, 2026
iShares Russell 2000 Growth ETF394K0.38%US$2.8MJun 30, 2026
Vanguard Health Care Index Fund279K0.27%US$2.09MMay 31, 2026
Vanguard Russell 2000 Index Fund231K0.22%US$1.73MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Enhanced Small Cap Core ETF196K0.19%US$1.39MJun 30, 2026
Vanguard Explorer Fund187K0.18%US$1.31MJul 31, 2026
Fidelity Total Market Index Fund183K0.18%US$1.37MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF181K0.17%US$1.29MJun 30, 2026
Dimensional U.S. Small Cap ETF175K0.17%US$1.23MJul 31, 2026
iShares Micro-Cap ETF151K0.14%US$1.07MJun 30, 2026
Fidelity Series Total Market Index Fund147K0.14%US$1.1MMay 31, 2026
U.S. Small Cap Portfolio142K0.14%US$998KJul 31, 2026
Schwab Small-Cap Index Fund110K0.11%US$770KJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.98,1440.09%US$697KJun 30, 2026
Small Company Growth Portfolio95,4160.09%US$677KJun 30, 2026
U.S. Micro Cap Portfolio81,6160.08%US$572KJul 31, 2026
Master Small Cap Index Series78,9230.08%US$560KJun 30, 2026
Nuveen Small Cap Blend Index Fund59,8820.06%US$420KJul 31, 2026
Schwab Total Stock Market Index Fund58,4640.06%US$410KJul 31, 2026
Fidelity ZERO Total Market Index Fund57,2100.05%US$401KJul 31, 2026
VIP Disciplined Small Cap Portfolio52,5690.05%US$373KJun 30, 2026
Virtus Biotech Clinical Trials Etf48,4900.05%US$340KJul 31, 2026
Vanguard Balanced Index Fund48,3160.05%US$343KJun 30, 2026
Fidelity Nasdaq Composite Index Fund47,1840.05%US$352KMay 31, 2026
EQ/2000 Managed Volatility Portfolio46,2940.04%US$329KJun 30, 2026
Water Island Event-Driven Fund42,0000.04%US$314KMay 31, 2026
Vanguard Institutional Total Stock Market Index Fund41,9340.04%US$298KJun 30, 2026
iShares Russell 2000 Value ETF39,7320.04%US$282KJun 30, 2026
Fidelity Small Cap Growth Index Fund39,3160.04%US$279KJun 30, 2026
Avantis U.S. Small Cap Equity ETF37,2820.04%US$278KMay 31, 2026
Fidelity ZERO Extended Market Index Fund36,1530.03%US$253KJul 31, 2026
U.S. Core Equity 2 Portfolio35,8500.03%US$251KJul 31, 2026
LVIP State Street Small-Cap Index Fund27,4000.03%US$195KJun 30, 2026
EQ/Small Company Index Portfolio25,9000.02%US$184KJun 30, 2026
Vanguard Russell 2000 Value Index Fund24,9090.02%US$186KMay 31, 2026
Small Cap Index Fund23,2760.02%US$165KJun 30, 2026
Nuveen Equity Index Fund22,3610.02%US$157KJul 31, 2026
Global X Russell 2000 ETF21,4150.02%US$150KJul 31, 2026
EQ/AB Small Cap Growth Portfolio21,3300.02%US$151KJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund16,8860.02%US$120KJun 30, 2026
Small Cap Index Fund16,4360.02%US$123KMay 31, 2026
State Street Small/Mid Cap Equity Index Portfolio15,8000.02%US$112KJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF15,6970.02%US$110KJul 31, 2026
Fidelity Flex Small Cap Index Fund14,9600.01%US$105KJul 31, 2026

This page holds 50 of 137 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Hopkins Janet Jill
Officer: Chief Medical Officer
Sale16,903USD 7.05US$119KNov 16, 2026
Gibney Anthony S
Officer: See Remarks
Sale12,824USD 6.42US$82,330Jun 16, 2026
Matrix Capital Management Company, LP
10% owner
Sale6,922,870USD 5.64US$39MMay 7, 2026
Kilroy Conor
Officer: See Remarks
Sale11,738USD 7.02US$82,401Apr 16, 2026

Big stakes

StakeStakeSharesDateFiling
Chen Yu9.99%10.4MSep 30, 2026Schedule 13G
Adage Capital Management, L.P.8.44%9.1MJun 30, 2026Schedule 13G
Frazier Life Sciences Public Fund, L.P.5.60%5.81MJun 30, 2026Schedule 13G
ADAR1 Capital Management, LLC5.20%5.39MSep 30, 2026Schedule 13G
ForGrowth III PA B.V.5.10%5.25MSep 25, 2026Schedule 13G
BlackRock, Inc.5.03%5.22MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jeremy Bender
Other companies: Bicara Therapeutics Inc. (Director · Since at least Jul 28, 2026); Mereo BioPharma Group plc (Non-Executive Director · Since at least Jan 1, 2024); Day One Biopharmaceuticals Inc (CHIEF EXECUTIVE OFFICER, Director · Since at least May 26, 2021); Fusion Pharmaceuticals Inc (Director · Oct 16, 2023 – Jun 4, 2024 · Past)
Director · Since at least Jul 7, 2026
Sapna Srivastava
Other companies: Alumis Inc. (Director · Since at least Jul 30, 2025); Nuvalent, Inc. (Director · Since at least Jun 18, 2025); Tourmaline Bio Inc. (Director · Since at least Jun 4, 2025)
Director · Since at least Jun 17, 2025
David Johnson
Other companies: Zentalis Pharmaceuticals, Inc. (Director · Since at least Jun 16, 2026); Dynavax Technologies Corporation (Vice President · Jun 2, 2019 – Mar 13, 2020 · Past)
Director · Since at least May 4, 2026
Teresa Bitetti
Other companies: Takeda Pharmaceutical Co. Ltd. (President, Global Oncology Business Unit · Since at least Jan 5, 2026); Fusion Pharmaceuticals Inc (Director · Oct 16, 2023 – Jun 4, 2024 · Past)
Director · Since at least Mar 31, 2025
Anthony S Gibney
Other companies: InflaRx N.V. (Director · Since at least Mar 18, 2026)
See Remarks · Since at least May 13, 2025
Antony Mattessich
Other companies: Ocular Therapeutix, Inc. (President and CEO, Director · Jun 20, 2017 – Feb 3, 2024 · Past)
Director · Since at least Oct 28, 2021
Mark Plavsic
Other companies: Fate Therapeutics, Inc. (Chief Technical Officer · Jun 14, 2021 – Jan 10, 2023 · Past)
Chief Technology Officer · Since at least Mar 15, 2024
Rajesh R Parekh
Other companies: Celldex Therapeutics, Inc. (Director · Dec 23, 2009 – Sep 22, 2010 · Past)
Director · Oct 28, 2021 – Jun 7, 2023 · Past
Amy ElazzouziPrincipal Accounting Officer, Senior Vice President of Finance and Treasurer · Since at least Oct 25, 2024
Anthony DanielsVice President, Therapeutic Area Head Ocular Oncology · Since at least Nov 5, 2026
All 20 people
PersonSeat
Conor KilroySee Remarks · Since at least Apr 16, 2026
Erica KratzChief Regulatory and Quality Officer · Since at least Aug 11, 2026
Giovanni MariggiDirector · Since at least Oct 28, 2021
Janet Jill HopkinsChief Medical Officer · Since at least Sep 1, 2026
Jill HopkinsChief Medical Officer, President of Research & Development · Since at least Jun 1, 2026
Julie PersonChief People Officer · Since at least Aug 11, 2026
Natalie HollesChief Executive Officer and President and member of the Board · Since at least May 19, 2026
Patrick NealonSenior Vice President, Clinical Development Operations · Since at least Nov 5, 2026
Pinos Elisabet de losSee Remarks, Director · Since at least Oct 28, 2021
Susan Abu-AbsiChief Operating Officer · Since at least Aug 10, 2026

Open People

Log in to ask 6ix AI your own questions about Aura Biosciences, Inc.